Cash conversion cycleWarning
현금전환주기(CCC) 3기 연속 확대 — 운전자본 경색·현금 회수 지연 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Korean Drug
014570 · KOSDAQ₩3,500+0.00%
2026-09-04 closeKorean Drug last closed at ₩3,500 (+0.00%) on 2026-09-04. Signals today: VCP. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
A+
Overall: 건강관리 10/291 · top 3%
Factor composite · relative position in sector
PER 12.85 · PBR 0.49 — own-history percentile 52/100 · 94/100
Open self-history band
PER52/100
PBR94/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 25 consecutive years · Raised 1 consecutive years · Yield 4.57% (based on 2025 payment of 160원) · 3-year growth -2.0%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 15.00
Distress
Grey
Safe
- Altman Z''
- 15.00
- Beneish M-Score
- -2.82
- Sloan accrual
- -2.11%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
8/9Strong
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score8/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Margin trendWarning
영업이익률 악화 (22.2% → 12.5%, -9.6%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Margin trendWarning
영업외손익 급변 (영업이익 대비 184% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 141 of 287, share 0.1%.
141 / 2870.1%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6고려제약0.1%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 13.9
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 12.5%
- Interest coverage
- 2,155.3x
- Return on equity (ROE)
- 3.8%
Operating margin −5pp
TolerableInterest coverageBase 2,155.3x adverse case 1,294.4x
Return on equity (ROE)Base 3.8% adverse case 7%
Revenue −15%
TolerableInterest coverageBase 2,155.3x adverse case 1,832x
Return on equity (ROE)Base 3.8% adverse case 9.9%
Interest rate +2pp
TolerableInterest coverageBase 2,155.3x adverse case 41.6x
Return on equity (ROE)Base 3.8% adverse case 11.4%
Interest coverage limit
Current margin 12.5ppInterest coverage limit at an operating margin of 0%
Interest expense coverage threshold
Connections
AI-extracted related companies · for reference
Suppliers
Competitors
동화약품Price comovement r=0.32 (1 year)광동제약Price comovement r=0.26 (1 year)대웅제약Price comovement r=0.19 (1 year)유한양행Price comovement r=0.21 (1 year)종근당Price comovement r=0.18 (1 year)한미약품Price comovement r=0.14 (1 year)녹십자Price comovement r=0.26 (1 year)셀트리온Price comovement r=0.26 (1 year)삼진제약Price comovement r=0.22 (1 year)보령Price comovement r=0.23 (1 year)일동제약Price comovement r=0.21 (1 year)동아에스티Price comovement r=0.32 (1 year)JW중외제약Price comovement r=0.24 (1 year)
Recent filings
Korean Drug's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About Korean Drug
- What technical signals does Korean Drug (014570) have?
- Korean Drug current technical signals: no active technical signal.
- Is Korean Drug a cup-and-handle pattern?
- No. Korean Drug has no valid cup-and-handle signal right now.
- What are Korean Drug's financials and valuation?
- Korean Drug's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy